MAPT and Alzheimer disease: Historically, AD drugs have tried to target Aβ fibril and plaque accumulation and tau tangles, as they are not only pathological hallmarks of AD, but studies have linked them mechanistically to memory, cognitive, and physical dysfunction (1, 3).